Expanding the Use of HCV Infected Organs and the Challenge of Third-Party Payers

Reem Daloul, Todd Pesavento, Anthony Michaels
American Journal of Transplantation 2020 January 22
Since the publication of the first two novel reports demonstrating the feasibility of using Hepatitis C virus nucleic acid test positive (HCV NAT+) organs into negative recipients1,2 , evidence regarding the safety of using HCV NAT+ organs have been mounting. However, the wide implementation of such a practice hinges on the ability to ensure timely delivery of direct acting antiviral (DAA) therapy after transplantation. To date, DAA coverage by third party payers for acute HCV infection cannot be guaranteed.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"